Latest news with #INCY
Yahoo
16-06-2025
- Business
- Yahoo
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing the imminent loss of exclusivity for its main medicine, Jakafi. In Q1 2025, Jakafi grew 24% year-over-year. According to management, three factors contributed to this growth. 10% came from demand, 7% from net pricing, and 7% from less destocking this year than in the same quarter last year. Looking ahead, Incyte Corporation (NASDAQ:INCY) anticipates that demand will be the only factor driving growth for the remainder of the year. To broaden its portfolio beyond Jakafi, however, the company intends to introduce four new products or indications in 2025, with the goal of generating an extra $1 billion in revenue by 2029. Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
16-06-2025
- Health
- Business Insider
Incyte announces data from two studies evaluating INCA033989
Incyte (INCY) announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in class, Incyte-discovered, targeted monoclonal antibody in patients with mutant calreticulin-expressing myeloproliferative neoplasms, MPNs. These data – featured today in the Late-Breaking Oral Session at the European Hematology Association 2025, EHA 2025, Congress in Milan, Italy – focus on the dose escalation portion of the studies in patients with high risk essential thrombocythemia who are resistant/intolerant to prior cytoreductive therapy. The studies evaluated the safety and efficacy of INCA033989 in patients with ET as measured by hematologic response and reduction in mutCALR variant allele frequency. Results as of April 4, 2025, showed rapid and durable normalization of platelet counts across all dose levels, with a trend toward improved responses in higher doses, in patients with ET treated with INCA033989. Notably, 86% of patients at doses 400 mg and above achieved a complete or partial hematologic response, with the majority of patients achieving complete response. Eighty-nine percent of evaluable patients showed a reduction in mutCALR VAF from baseline. A partial molecular response was observed in 21% of evaluable patients after only 3 cycles of treatment.
Business Insider
13-06-2025
- Health
- Business Insider
Incyte's retifanlimab meets primary endpoint in carcinoma Phase 3 trial
Incyte (INCY) announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab – Zynyz -, a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer, or SCAC, who have not been previously treated with systemic chemotherapy, were published in The Lancet. The study met its primary endpoint by demonstrating a statistically significant improvement in progression-free survival in patients with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy. Adding retifanlimab to carboplatin and paclitaxel resulted in a clinically meaningful 37% reduction in the risk of progression or death. Patients in the retifanlimab and chemotherapy combination group achieved a median PFS of 9.3 months vs. 7.4 months for patients in the placebo combination group. A consistent benefit in PFS in favor of retifanlimab plus chemotherapy was observed for all pre-defined subgroups with sufficient patients for comparison. A clinically meaningful 6-month difference in overall survival was observed at the interim analysis. Interim OS results were not statistically significant, and patients continue to be followed for the final key secondary OS analysis. Overall response rate to treatment was improved by the addition of retifanlimab to the chemotherapy and the median duration of response was approximately doubled. No new safety signals were observed and safety was consistent with chemotherapy plus checkpoint inhibitor regimens.
Business Insider
05-06-2025
- Business
- Business Insider
Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)
Evercore ISI analyst maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $73.00. The company's shares closed yesterday at $67.42. Confident Investing Starts Here: In addition to Evercore ISI, Incyte also received a Hold from William Blair's Matt Phipps in a report issued yesterday. However, on the same day, BMO Capital maintained a Sell rating on Incyte (NASDAQ: INCY). Based on Incyte's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.05 billion and a net profit of $158.2 million. In comparison, last year the company earned a revenue of $880.89 million and had a net profit of $169.55 million Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Earlier this month, Thomas Tray, the CAO of INCY sold 1,614.00 shares for a total of $105,515.61.
Business Insider
15-05-2025
- Business
- Business Insider
Incyte (INCY) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Incyte (INCY – Research Report) yesterday and set a price target of $89.00. The company's shares closed yesterday at $61.16. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma. According to TipRanks, Ahmad has an average return of -5.3% and a 43.00% success rate on recommended stocks. In addition to Bank of America Securities, Incyte also received a Buy from TD Cowen's Marc Frahm in a report issued on April 29. However, on May 13, RBC Capital maintained a Hold rating on Incyte (NASDAQ: INCY). INCY market cap is currently $11.78B and has a P/E ratio of 188.15. Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Most recently, in March 2025, Barry Flannelly, the EVP & General Manager US of INCY sold 19,807.00 shares for a total of $1,340,655.93.
